Skip to main content
. 2006 Dec 14;109(7):3080–3083. doi: 10.1182/blood-2006-06-031096

Table 1.

Selected demographic, clinical, and outcome variables for S9400 patients included in the Q-RT-PCR analysis, by CTGF expression level tertile

Variable CTGF expression
Total
Low Intermediate High
No. of patients 27 26 26 79
Median age, y (range) 31 (18-59) 32 (17-62) 41 (18-64) 35 (17-64)
FAB, no. (%)
    L1 9 (33) 6 (23) 8 (31) 23 (29)
    L2 16 (59) 17 (65) 18 (69) 51 (65)
    NA 2 (7) 3 (12) 0 (0) 5 (6)
Lineage, no. (%)
    T 9 (33) 3 (12) 1 (4) 13 (13)
    B 11 (41) 19 (73) 20 (77) 50 (63)
    NA 7 (26) 4 (15) 5 (19) 16 (20)
Performance status, no. (%)
    0 13 (48) 14 (54) 12 (46) 39 (49)
    1 11 (41) 9 (35) 14 (54) 34 (43)
    2 2 (7) 1 (4) 0 (0) 3 (4)
    NA 1 (4) 2 (8) 0 (0) 3 (4)
Median WBC count, × 109/L (range) 19.5 (2.1-396.6) 27.3 (0.6-148.0) 28.4 (3.3-150.0) 23.4 (0.6-396.6)
Median PB blasts, % (range)* 49 (1-96) 60 (0-94) 48 (0-95) 56 (0-96)
Median BM blasts, % (range) 80 (31-99) 94 (72-99) 90 (58-99) 90 (31-99)
CD34, % positive cells 8 (0-96) 51 (1-95) 81 (8-98) 64 (0-98)
Cytogenetics, no. (%)
    UNF 3 (11) 12 (46) 10 (38) 25 (32)
    NL 6 (22) 3 (12) 4 (15) 13 (16)
    Others 14 (52) 7 (27) 2 (8) 23 (29)
    NA 4 (15) 4 (15) 10 (38) 18 (23)
Complete response, no. (%) 21 (81) 22 (85) 21 (81) 64 (82)
Resistant disease, no. (%) 1 (4) 2 (8) 3 (12) 6 (8)
5-y overall survival, % (95% CI) 58 (38-78) 42 (23-61) 11 (0-24) 37 (26-48)
5-y disease-free survival,§ % (95% CI) 54 (32-76) 41 (20-61) 5 (0-14) 33 (21-45)

NA indicates not available; UNF, unfavorable; NL, normal; CI, confidence interval.

*

N = 74.

N = 64.

N = 67.

§

Disease-free survival was measured from the date the complete response was established until relapse of leukemia or death from any cause, with observations censored for patients last known to be alive without report of relapse.